Patents by Inventor Ziad Mallat

Ziad Mallat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and pharmaceutical compositions for the treatment of obesity
    Patent number: 11752131
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of obesity. In particular, the present invention relates to a method of treating obesity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 12, 2023
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES
    Inventors: Fatima-Soraya Taleb, Ziad Mallat, Alain Tedgui
  • A B Cell Depleting Agent for the Treatment of Atherosclerosis
    Publication number: 20200376118
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 3, 2020
    Inventors: Ziad Mallat, Hafid Ait-Oufella, Alain Tedgui, Thomas Tedder
  • A B Cell Depleting Agent for the Treatment of Atherosclerosis
    Publication number: 20190365890
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.
    Type: Application
    Filed: July 9, 2019
    Publication date: December 5, 2019
    Inventors: Ziad Mallat, Hafid Ait-Oufella, Alain Tedgui, Thomas Tedder
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OBESITY
    Publication number: 20180369198
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of obesity. In particular, the present invention relates to a method of treating obesity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor.
    Type: Application
    Filed: February 17, 2017
    Publication date: December 27, 2018
    Inventors: Fatima-Soraya TALEB, Ziad MALLAT, Alain TEDGUI
  • Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
    Patent number: 9688767
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from myocardial infarction or the recurrence of a myocardial infarction. The method comprises the steps of i) determining the expression level of BAFF in a sample from the patient, ii) comparing the expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 27, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes, Universite Pierre et Marie Curie-UPMC, Assistance Publique-Hopitaux de Paris (APHP)
    Inventors: Ziad Mallat, Alain Tedgui, Tabassome Simon, Nicolas Danchin
  • Use of IL-18BP for treatment of peripheral vascular diseases
    Patent number: 9592267
    Abstract: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: March 14, 2017
    Assignee: MERCK SERONO SA
    Inventors: Yolande Chvatchko, Alain Tedgui, Ziad Mallat
  • Method for use in the treatment of aneurysm
    Patent number: 9573997
    Abstract: The present invention relates to a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression for use in the treatment or the prevention of aneurysm. In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 21, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes
    Inventors: Ziad Mallat, Soraya Taleb, Alain Tedgui
  • Method of treating peripheral vascular diseases using IL-18 inhibitors
    Patent number: 9566313
    Abstract: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: February 14, 2017
    Assignees: MERCK SERONO SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Yolande Chvatchko, Alain Tedgui, Ziad Mallat
  • Method and Pharmaceutical Composition for use in the Treatment and Prediction of Myocardial Infarction
    Publication number: 20160024218
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering of myocardial infarction or the recurrence of a myocardial infarction in a patient who has suffered from a myocardial infarction comprising the steps consisting of i) determining the expression level of BAFF in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventors: Ziad Mallat, Alain Tedgui, Tabassome Simon, Nicolas Danchin
  • SPLA2 CARDIOVASCULAR PROGNOSTIC AND DIAGNOSTIC MARKER
    Publication number: 20150299763
    Abstract: A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, comprising: determining the sPLA2 activity of said patient, comparing said activity to a predetermined value, a higher sPLA2 activity of the patient as compared to the predetermined value being indicative of an increased risk of mortality or of a cardiac and/or vascular event.
    Type: Application
    Filed: April 27, 2015
    Publication date: October 22, 2015
    Inventors: Ziad MALLAT, Alain TEDGUI, Philippe Gabriel STEG, Jean-Marie FREYSSINET, Joelle BENESSIANO
  • COMBINATION OF SPLA2 ACTIVITY AND LP(A) CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT
    Publication number: 20150132771
    Abstract: The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) s PLA2 activity and b) Lipoprotein(a), —combining said measurements, the combined value of s PLA2 activity and Lp(a) being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.
    Type: Application
    Filed: December 17, 2014
    Publication date: May 14, 2015
    Inventors: Ziad Mallat, Sotirios Tsimikas
  • METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR EVENT IN A SUBJECT
    Publication number: 20150104463
    Abstract: The present invention relates to in vitro methods and kits for predicting the risk of having a cardiovascular event in a subject. More particularly, the invention relates to an in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the step of measuring the level of IL-17 in a blood sample obtained from said subject.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE PARIS DESCARTES
    Inventors: Ziad MALLAT, Alain TEDGUI, Tabasomme SIMON, Nicolas DANCHIN
  • Method and Pharmaceutical Composition for use in the Treatment or the Prevention of Aneurysm
    Publication number: 20150050290
    Abstract: The present invention relates to a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression for use in the treatment or the prevention of aneurysm. In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 19, 2015
    Applicant: Universite Paris Descartes
    Inventors: Ziad Mallat, Soraya Taleb, Alain Tedgui
  • METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR EVENT IN A SUBJECT
    Publication number: 20140004540
    Abstract: The present invention relates to in vitro methods and kits for predicting the risk of having a cardiovascular event in a subject. More particularly, the invention relates to an in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the step of measuring the level of IL-17 in a blood sample obtained from said subject.
    Type: Application
    Filed: January 13, 2012
    Publication date: January 2, 2014
    Applicant: UNIVERSITE PARIS DESCARTES
    Inventors: Ziad Mallat, Alain Tedgui, Tabassome Simon, Nicolas Danchin
  • Methods for producing a non human model for aortic aneurysm
    Patent number: 8586822
    Abstract: The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: November 19, 2013
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Pierre Louis Tharaux, Hafid Ait-Oufella, Alain Tedgui, Ziad Mallat
  • A B Cell Depleting Agent for the Treatment of Atherosclerosis
    Publication number: 20130224215
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.
    Type: Application
    Filed: March 8, 2013
    Publication date: August 29, 2013
    Inventors: Ziad Mallat, Hafid Ait-Oufella, Alain Tedgui, Thomas Tedder
  • Combination of sPLA2 type IIA mass and OXPL/APOB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
    Patent number: 8383355
    Abstract: The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: February 26, 2013
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), The Regents of the University of California
    Inventors: Ziad Mallat, Alain Tedgui, Sotirios Tsimikas, Joseph Witztum
  • Combination of sPLA2 activity and oxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
    Patent number: 8361732
    Abstract: The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: January 29, 2013
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), The Regents of the University of California, Universite Paris Diderot—Paris 7
    Inventors: Ziad Mallat, Alain Tedgui, Sotirios Tsimikas, Joseph Witztum
  • COMBINATION OF sPLA2 TYPE IIA MASS AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT
    Publication number: 20130017557
    Abstract: The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.
    Type: Application
    Filed: December 8, 2009
    Publication date: January 17, 2013
    Inventors: Ziad Mallat, Alain Tedgui, Sotirios Tsimikas, Joseph Witztum
  • COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS
    Publication number: 20120321650
    Abstract: Epitopes derived from a protein present in an atherosclerotic plaque, such as apolipoprotein B-100, are presented. The epitopes can be used in a method of treating atherosclerosis by continuous subcutaneous or transcutaneous administration of a therapeutically effective amount of the epitope to a subject. Administering the epitope to the subject can induce a specific regulatory immune response, such as a Treg response. A composition or patch containing the epitope and adapted for the prophylactic or therapeutic treatment of a subject are also presented.
    Type: Application
    Filed: August 1, 2012
    Publication date: December 20, 2012
    Applicant: Institut National De La Sante Et De La Recherche Medicale (Inserm)
    Inventors: Alain TEDGUI, Ziad MALLAT